Follistatin is a protein the body makes itself, given by injection or gene therapy to build muscle by blocking the body's brake on growth. Injecting a follistatin-based protein into one muscle makes it measurably bigger, but not reliably stronger. Follistatin running high on its own tracks with diabetes, stroke and kidney disease, nearly half the material sold online is not follistatin, and gene transfer cannot be undone. (Full Review)

Protocol

Intramuscular gene transfer, the trial regimen

3 × 10¹¹ or 6 × 10¹¹ vector genomes per kilogram per leg

Adeno-associated virus serotype 1 carrying FS-344, injected bilaterally into quadriceps under image guidance; single administration.

Intramuscular gene transfer, the longevity-clinic regimen

5 × 10¹⁰ or 1 × 10¹¹ vector genomes per kilogram

Adeno-associated virus serotype 9 carrying follistatin, distributed bilaterally across quadriceps, gluteus maximus, gastrocnemius and biceps brachii, with rapamycin cover.

Engineered local protein, the discontinued approach

150–240 mg per muscle every three weeks

ACE-083 injected into a named muscle for up to twelve months. Enlarges only the injected muscle; the programme was stopped.

Time to effect

Muscle volume

Three to six months

Measured at three to six months in every protocol.

Engineered-protein volume gain

By six months

Significant volume gain with the engineered protein.

Walking distance

Six months to one year

Assessed in gene-transfer trials at six months and one year.

Benefits

High: Increased skeletal muscle volume at the injected site

Low: Muscle fibre hypertrophy and reduced fibrosis after gene transfer; improved walking distance in muscle-wasting disease; muscle strength, conflicted; reduced fat inside the treated muscle, conflicted

Speculative: Whole-body lean mass gain with fat loss. Not central to muscle growth: reduced biological age; reduced joint damage and metabolic inflammation

Contraindications

Any cancer history or hereditary cancer syndrome (BRCA1/2, Lynch, Li-Fraumeni) without clearance

Pregnancy, breastfeeding, premenopausal status, or no contraception for six months afterwards

Diabetes, fasting glucose ≥126 mg/dL, or haemoglobin A1c ≥6.5%

Chronic kidney disease stage 3–5 (filtration below 60 mL/min/1.73 m²)

Cirrhosis, viral hepatitis, or transaminases above 1.5 times normal

Dysferlinopathy

Heart failure, ejection fraction below 50%, prior infarction or stroke at any interval, or left ventricular wall thickness ≥15 mm

Prior adeno-associated virus gene therapy, or antibody titre above 1:100

Active infection, tuberculosis, hepatitis B or C, or human immunodeficiency virus

Inflammatory myopathy, connective-tissue disease, or prior rhabdomyolysis

Anti-vascular endothelial growth factor agents (bevacizumab, ranibizumab) with a growth factor plasmid

Key Interactions

Immunosuppressants (rapamycin, prednisolone, tacrolimus)

Corticosteroids (prednisone, dexamethasone)

Anticoagulants and antiplatelets (warfarin, apixaban, clopidogrel)

Statins and other muscle-toxic drugs (simvastatin, daptomycin, colchicine)

Muscle-targeting interventions (resistance training, blood-flow restriction training, growth hormone secretagogues such as ipamorelin)

Androgens and anabolic steroids (testosterone, oxandrolone, androgen receptor modulators)

Incretin mimetics (semaglutide, tirzepatide)

Anti-inflammatories (ibuprofen, naproxen, aspirin)

Supplements with myostatin-pathway claims (epicatechin, egg-yolk isolates, sulforaphane)

Supplements shifting creatine kinase (creatine monohydrate, high-dose caffeine)

Risk & Side Effects

High: Injection-site reactions

Medium: Higher circulating follistatin tracks with cardiometabolic disease

Low: Vector immune response and liver injury; misidentified and adulterated grey-market product; vascular and mucosal effects of broad pathway blockade

Speculative: Suppression of follicle-stimulating hormone; tumour-promoting activin blockade; tendon and connective-tissue weakening

Monitoring

Marker	Target	Why
Serum follistatin	No set target; fold-change from own baseline (roughly 1–10 ng/mL)	Confirms the product expressed at all
Fasting insulin	2–5 µIU/mL	Earliest sign of insulin resistance linked to higher follistatin
Haemoglobin A1c	Below 5.3%	Confirms glucose handling has not drifted
Fasting glucose	75–85 mg/dL	Complements insulin for the same signal
Alanine aminotransferase	Below 20 U/L (men), below 17 U/L (women)	Detects vector-related liver injury while reversible
Creatine kinase	45–200 U/L	Separates injection trauma and myopathy from expected soreness
Follicle-stimulating hormone	Men 1.5–8 IU/L; postmenopausal women 25–135 IU/L	Detects suppression of the activin axis follistatin acts on
Appendicular lean mass index	Men 8.0–9.5 kg/m²; women 6.5–7.5 kg/m²	The actual outcome being purchased
Estimated glomerular filtration rate	Above 90 mL/min/1.73 m²	Higher follistatin associates with chronic kidney disease
High-sensitivity C-reactive protein	Below 0.5 mg/L	Tracks the inflammatory tone that activin blockade shifts

Cadence: Baseline before dosing; liver enzymes and blood counts weekly for eight weeks; then at three, six and twelve months with glucose handling, follistatin, hormones and body composition; thereafter every six to twelve months indefinitely. Vector antibody titre once, before dosing.

Qualitative Assessment

Perceived strength at a fixed working weight, recorded as repetitions at a constant load
Recovery time between hard training sessions
Joint and tendon comfort during loaded movement, the predicted lagging element
Visible limb girth asymmetry, expected after single-muscle injection
Energy, appetite and sleep quality
Nosebleeds, visible small dilated surface vessels, or unexplained bruising

Follistatin for Muscle Growth

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment